SR-717 is a cGAMP analog, a non-nucleoside STING agonist that induces a "closed" activation conformation of STING. SR-717 has antitumor activity and promotes activation of immune cells and cross-presentation of antigens.

METHODS: Macrophage THP1 were treated with SR-717 (3.6 µM) for 10 min-6 h. The expression levels of target proteins were detected using Western Blot.
RESULTS: SR-717 activates p-STING, and its downstream p-TBK1, p-IRF3, p-p65, p-STAT1 and p-STAT3. [1]
METHODS: Primary human peripheral blood mononuclear cell PBMCs were treated with SR-717 (10 µM) for 2-6 h. Gene expression levels were detected using RT-qPCR.
RESULTS: SR-717 stimulated the activation of IFNB1, CXCL10 and IL6. [1]

METHODS: To test the antitumor activity in vivo, SR-717 (30 mg/kg) was injected intraperitoneally into WT or Stinggt/gt C57BL/6 mice bearing mouse cutaneous melanoma tumor B16.F10 once daily for seven days.
RESULTS: SR-717 inhibited tumor growth as well as prolonged the survival time of mice with rhabdomyosarcoma. The antitumor effect of SR-717 showed an enforced dependence on STING expression, and a lack of activity was observed in Stinggt/gt mice. [1]
METHODS: To assay antitumor activity in vivo, SR-717 (10 mg/kg) was administered intravenously three times every two days to C57BL/6 mice harboring mouse cutaneous melanin tumor B16.F10.
RESULTS: SR-717 has anti-tumor activity in vivo and prolongs survival. [2]